Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
June 05, 2024 08:30 ET
|
Adial Pharmaceuticals, Inc
Study intended to optimize design elements needed for the upcoming US Pivotal Phase 3 studiesand support ongoing partnership discussions Topline results expected in early Q4 2024 GLEN ALLEN,...
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
May 29, 2024 08:30 ET
|
Adial Pharmaceuticals, Inc
GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 15, 2024 08:30 ET
|
Adial Pharmaceuticals, Inc
GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
April 22, 2024 08:30 ET
|
Adial Pharmaceuticals, Inc
GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
April 10, 2024 08:30 ET
|
Adial Pharmaceuticals, Inc
GLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update
April 02, 2024 08:30 ET
|
Adial Pharmaceuticals, Inc
Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to...
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
March 01, 2024 19:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
February 28, 2024 09:30 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
February 13, 2024 09:15 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Announces Appointment of Tony Goodman as Chief Operating Officer
January 18, 2024 08:30 ET
|
Adial Pharmaceuticals, Inc
Charlottesville, Va., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...